Introduction and Objective: Chronic disease management relies on patient adherence to interventions. We analyzed glucose measurements from 3803 diabetic patients during their first 6 months in a coaching program. We observed decreasing glucose readings, validated by HbA1c reductions. Subjects who monitored more frequently demonstrated greater decreases in HbA1c levels. Methods: Primary care physicians enrolled patients with diabetes into the iHealth Unified Care program during 2019-2023. Patients received Bluetooth-connected devices and a mobile app to monitor blood glucose and other vital signs. Participants underwent laboratory tests measuring markers such as HbA1c. We categorized participants into three adherence groups based on monitoring patterns: low adherence (2.43 average measurements per week), medium (5.62), and high (12.78). Initial analysis revealed a downward trend in HbA1c values over time, with higher adherence correlating with better outcomes. A linear mixed effects model was used to account for individual differences and assess program effectiveness. Results: Our model demonstrated that HbA1c decreased by 0.003% per week (p = 0.039). Using the low adherence group as reference, higher adherence was associated with greater reductions in HbA1c. Patients in the highest adherence group showed an additional decrease of 0.1724% (p = 0.093), while medium adherence showed an additional decrease of 0.1577% (p = 0.005). Compared to obese patients, healthy BMI was associated with lower HbA1c (-0.143%, p=0.050). Current smoking was associated with higher HbA1c (+0.500%, p<0.001). Conclusion: Our analysis demonstrated that higher adherence to monitoring practices significantly improved glycemic control. Patients with greater adherence experienced more substantial improvements in glucose readings. These findings highlight the critical role of consistent monitoring in effectively managing chronic diseases, emphasizing the need for patient engagement for optimal health outcomes. Y. Huang: None. N. Nagesh: None. A. Subramanian: None. Z. Liu: None. R.S. Stafford: None. A. Rahmani: None. W. Hou: Employee; iHealth Labs, Inc. L. Wang: None.
Introduction: FDA guidance recommends continuous glucose monitoring (CGM) for diabetes clinical trials. Real-time monitoring in such trials demands high-speed data frameworks. Here, we sought to develop a fully GxP-compliant platform that integrates with CGM devices and rapidly transmits regulatory submission quality data to study servers. Methods: Software acquired glucose readings directly from Dexcom G6 CGM transmitters and sensors via Bluetooth. Live transmitter samples were considered real-time readings; backfill samples were excluded from real-time classification. Software synchronized with study servers after each sample acquisition, pending network connectivity. Descriptive statistics were evaluated for this pilot study. Results: CGM readings (n=5,996) were generated over a 24 day study period. Median inter-sample interval was 5.0 minutes, and 99.4% of all sample intervals were between 4.9 and 5.1 minutes. Sample validity was high (98.6%), where 1.3% of samples were lost to sensor warmup and 0.05% of samples were lost to sensor error. Real-time measurements made up 96.4% of readings. Median transmitter sync time was 0.50 seconds (IQR: 0.26 - 0.75 seconds). Server upload times were fastest at 12 seconds; median upload time was 10.3 minutes (IQR: 5.3 - 25.3 minutes). Participant showed normal glycemic variability (19.7%), time-in-range (97.3%), and glycemic risk index (3.6%), with few Level-1 (n=3) and Level-2 (n=1) hypoglycemic events. Conclusions: We developed a fully GxP-compliant high-speed data platform directly integrated with CGM devices. There is potential for low latency data availability - on the order of seconds - and further investigation is required to understand sources of server upload lag, for example network connectivity. Future development of this platform will include integrated hypo forms triggered by CGM data streams. Further work is needed to understand network dynamics of this framework in a larger study cohort. Disclosure D. Anderson: Employee; Clinical ink. M. Merickel: None. A. Best: Employee; Clinical Ink. B.T. Severson: Employee; Clinical Ink. C.B. Djurhuus: Stock/Shareholder; Novo Nordisk A/S. J. Goldman: Employee; Clinical ink.
The Golden Gate Bridge will finally erect a barrier at the end of this year. The death toll since its completion in 1937 is about 2000. Two a month still jump to their deaths. The bridge is tragically known as the number one suicide site in the world.
1584 Objectives: 18F-DCFPyL is a promising 18F-labeled agent for PSMA PET imaging, available at our institution through a research access program. Here we compared 18F-DCFPyL PET/CT and 18F-NaF PET/CT for the detection of skeletal metastases in patients with biochemically recurrent prostate cancer (BCR PC). Methods: We prospectively enrolled 50 patients (52-91 years old, 71.2 ± 7.4 years) who had 18F- DCFPyL PET/CT at BCR PC after definitive treatment with prostatectomy (30 patients) and/or radiation therapy (20 patients). A total of 16 of the 50 patients (63-86 years old, 73.6 ± 5.9 years) also had 18F-NaF PET/CT for identification of bone metastases. Up to 7 bone lesions were recorded per patient for each tracer. Results: Three patients did not have bone metastases. A total of 41 skeletal lesions were found. 18F DCFPyL PET/CT identified 32 bone lesions (78%) and 18F NaF PET/CT identified 35 lesions (85.4%). Congruent findings between 18F-DCFPyL and 18F NaF were found in 26/41 (63.4%) lesions. 18F DCFPyL identified 1 lesion missed on 18F NaF in 4 participants (4/41, 9.8%). However, 18F DCFPyL was negative in 2 patients with lesions found on 18F NaF (4/41 lesions, 9.8%). CT alone identified 21 lesions (51.2%). Conclusions: The performance of 18F DCFPyL PET/CT for detecting bone metastases is similar to that of 18F NaF PET/CT. Taken together with the accuracy of 18F-DCFPyL PET/CT in the detection of non-bone metastases and disease at low PSA presented separately, 18F DCFPyL PET/CT may be used as a “one stop shop” for evaluation of patients with BCR PC. However, more patients have to be evaluated to support these findings.